Ginkgo Bioworks Holdings (DNA) Total Current Liabilities (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Total Current Liabilities of $79.6 million for Q1 2026, down 17.06% on a QoQ basis from $96.0 million in Q4 2025, and down 31.19% year-over-year from $115.7 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $79.6 million for Q1 2026.
- Quarterly Total Current Liabilities fell 31.19% year-over-year to $79.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.6 million (down 31.19% YoY) and the FY2025 annual result came in at $96.0 million, down 10.53% from the prior year.
- Total Current Liabilities was $79.6 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $96.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $191.7 million in Q1 2023 and bottomed at $79.6 million in Q1 2026.
- A 5-year average of $137.6 million and a median of $135.0 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 11100.25% — and 2025, when it slumped 41.79%.
- Ginkgo Bioworks Holdings' Total Current Liabilities stood at $173.0 million in 2022, then dropped by 5.26% to $163.9 million in 2023, then sank by 34.54% to $107.3 million in 2024, then slipped by 10.53% to $96.0 million in 2025, then decreased by 17.06% to $79.6 million in 2026.
- Business Quant data shows DNA's Total Current Liabilities at $79.6 million in Q1 2026, $96.0 million in Q4 2025, and $115.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 79.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.60 Mn |
| Dec 31, 2025 | 95.97 Mn |
| Sep 30, 2025 | 115.28 Mn |
| Jun 30, 2025 | 96.72 Mn |
| Mar 31, 2025 | 115.67 Mn |
| Dec 31, 2024 | 107.27 Mn |
| Sep 30, 2024 | 114.43 Mn |
| Jun 30, 2024 | 166.15 Mn |
| Mar 31, 2024 | 169.04 Mn |
| Dec 31, 2023 | 163.86 Mn |
| Sep 30, 2023 | 168.46 Mn |
| Jun 30, 2023 | 163.33 Mn |
| Mar 31, 2023 | 191.70 Mn |
| Dec 31, 2022 | 172.96 Mn |
| Sep 30, 2022 | 124.82 Mn |
| Jun 30, 2022 | 135.02 Mn |
| Mar 31, 2022 | 159.25 Mn |
| Dec 31, 2021 | 134.76 Mn |
| Sep 30, 2021 | 90.31 Mn |
| Jun 30, 2021 | 4.69 Mn |